TP53 alterations independently predicted inferior remission, EFS, and OS after CAR T-cell therapy in relapsed/refractory B-ALL.

Over the course of treatment, patients with relapsed/refractory acute myeloid leukemia (AML) may acquire new TP53 mutations, making ongoing monitoring for mutations crucial. “New novel therapies ...

Patients with myelofibrosis (MF) with single-hit mutations had similar outcomes to patients with wild-type TP53. People with myelofibrosis (MF) who undergo hematopoietic stem cell transplantation ...

Among patients with chondrosarcomas, the most common primary bone tumor in adults, the presence of a TP53 gene mutation has been found to be associated with worse overall survival and metastasis-free ...

Men who have mutations in a gene called TP53 have a high risk of developing aggressive prostate cancer, a multicenter research team in the United States has found. The findings were reported in the ...

In a recent study published in Nature Genetics, researchers performed an allelic-level single-cellular multi-omics evaluation of hematopoietic stem/progenitor cells (HSPCs) obtained from individuals ...

The TP53 gene provides instructions for making a protein called tumor protein p53 (or p53). This protein regulates cell division by keeping cells from growing and dividing too fast or in an ...

Credit: Getty Images. The treatment was unlikely to demonstrate a survival benefit. Gilead has discontinued the ENHANCE-2 study evaluating magrolimab in patients with acute myeloid leukemia (AML) with ...

Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study. This is an ASCO Meeting ...

—A study of 1230 individuals with chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis demonstrated that patients with wild type TP53 had longer time to first treatment and ...